Abstract
TLRs are very important players to regulate innate immune responses. TLR4 controls the host defense by sensing an exotic pathogen, such as lipopolysaccharides. At the same time, some endogenous proteins, including HMGB1 and S100A8, could also function to be a ligand to elicit inflammatory reactions. These facts make TLR4 signaling system very complicated. For instance, the application of TLR4 ligands in cancer therapies is desirable for enhancement of anti-tumor immunity in terms of its reparative nature, but undesirable for enhancement of metastatic growth of cancer cells. In this manuscript, in order to make a novel molecular design to disrupt an interaction between TLR4/MD-2 and endogenous ligands, we provide a potential binding style of the TLR4/MD-2 complex with HMGB1 by using their 3D structural data and docking simulations, and also discuss S100A8 binding to TLR4/MD-2.
Keywords: Endogenous ligand, HMGB1, immunity, inflammatory, S100A8, TLR4/MD-2.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example
Volume: 15 Issue: 2
Author(s): Yoshiro Maru, Takeshi Tomita, Atsuko Deguchi, Katsuaki Ieguchi, Morichika Takita, Fujiko Tsukahara, Kazuhiro Takemura, Akio Kitao and Fabian Gusovsky
Affiliation:
Keywords: Endogenous ligand, HMGB1, immunity, inflammatory, S100A8, TLR4/MD-2.
Abstract: TLRs are very important players to regulate innate immune responses. TLR4 controls the host defense by sensing an exotic pathogen, such as lipopolysaccharides. At the same time, some endogenous proteins, including HMGB1 and S100A8, could also function to be a ligand to elicit inflammatory reactions. These facts make TLR4 signaling system very complicated. For instance, the application of TLR4 ligands in cancer therapies is desirable for enhancement of anti-tumor immunity in terms of its reparative nature, but undesirable for enhancement of metastatic growth of cancer cells. In this manuscript, in order to make a novel molecular design to disrupt an interaction between TLR4/MD-2 and endogenous ligands, we provide a potential binding style of the TLR4/MD-2 complex with HMGB1 by using their 3D structural data and docking simulations, and also discuss S100A8 binding to TLR4/MD-2.
Export Options
About this article
Cite this article as:
Maru Yoshiro, Tomita Takeshi, Deguchi Atsuko, Ieguchi Katsuaki, Takita Morichika, Tsukahara Fujiko, Takemura Kazuhiro, Kitao Akio and Gusovsky Fabian, Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example, Endocrine, Metabolic & Immune Disorders - Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/187153031502150522123746
DOI https://dx.doi.org/10.2174/187153031502150522123746 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Electrical Impedance Scanning - A New Diagnostic Tool in Cancer Detection: Current Status and Recent Developments
Current Medical Imaging The Biological Functions of NF-κB1 (p ) and its Potential as an Anti-Cancer Target
Current Cancer Drug Targets Annona sp: Plants with Multiple Applications as Alternative Medicine - A Review
Current Bioactive Compounds Novel Strategies and Model Studies for Colon Targeted Drug Delivery
Drug Delivery Letters Editorial (Thematic Issue: Melanoma Treatment: Finally Some Light at the End of the Tunnel?)
Clinical Cancer Drugs PP2A in the Regulation of Cell Motility and Invasion
Current Protein & Peptide Science Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Proteomics Analogs of Cinnamic Acid Benzyl Amide As Nonclassical Inhibitors of Activated JAK2 Kinase
Current Cancer Drug Targets De Novo Malignancies After Organ Transplantation: Focus on Viral Infections
Current Molecular Medicine Application of NMR to the Study of Cells and Body Fluids
Current Organic Chemistry Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine NO News is not Necessarily Good News in Cancer
Current Cancer Drug Targets Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design The Role of the Calcium-Sensing Receptor in Bone Biology and Pathophysiology
Current Pharmaceutical Biotechnology Why Anticancer Nanomedicine Needs Sugars?
Current Medicinal Chemistry